Universal penny stocks focus is on Hot Penny Stocks that trade on OTCBB and OTC markets, which are mostly referred to as “penny stocks”. These Penny Stocks could offer the greatest potential return on your short or long term investment. Sign up for our free newsletter before you miss the next alert.
Scottsdale, AZ -- (SBWIRE) -- 01/28/2013 -- Keryx Biopharmaceuticals (NASDAQ:KERX) was trading higher by +1.37 points or +40.52% to 4.82. So far, around 13.47 million shares have changed hands in this session. After opening at $5.10, the stock hit as high as $5.11. However, it traded between $1.28 and $5.19 over the last twelve months. Keryx Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of pharmaceutical products for the treatment of renal disease in the United States.
What was the Moving Force behind KERX On Bullish Run? Read This Research Report
Pfizer Inc. (NYSE:PFE) was at $26.98, showing a -0.07% decrease. Around 7.82 million shares have been traded, versus an-average trading volume of 31.89 million shares. The company is now valued at around $198.79 billion. Pfizer Inc., a biopharmaceutical company, engages in the discovery, development, manufacture, and sale of medicines for people and animals worldwide. It primarily offers Celebrex, Chantix/Champix, Lipitor, Lyrica, Premarin, Pristiq, and Viagra pharmaceutical products in the therapeutic and disease areas of Alzheimer?s disease.
Has PFE Found The Bottom and Ready To Move Up? Find Out Here
Bristol Myers Squibb Co. (NYSE:BMY) moved -0.76 per cent lower at $36.41 and is trading between $36.04 and $36.42 after opening the day at $36.18. Its performance over the last five days remained +5.63%, which stands at +14.11% for a month. Going back further than one month, 1-year performance after recent close was +12.73%. Bristol-Myers Squibb Company, a biopharmaceutical company, discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products that help patients prevail over serious diseases worldwide.
Has BMY Found The Bottom And Ready To Gain Momentum? Find Out Here
Abbott Laboratories (NYSE:ABT)’s shares rose today, gaining +0.51 per cent to $32.96. The stock is up around +0.61% in 2013 and +19.77% for the last 12 months. Around 3.32 million shares changed hands so far in this session compared to an-average trading volume of 11.70 million shares. Abbott Laboratories engages in the discovery, development, manufacture, and sale of health care products worldwide. It offers diagnostic systems and tests, such as immunoassay and clinical chemistry systems; assays for screening and/or diagnosis for drugs of abuse, cancer, therapeutic drug monitoring.
For How Long ABT will fight for Profitability? Read This Trend Analysis Report
The share price of Merck & Co., Inc. (NYSE:MRK) is ranging between $43.20 and $43.50. It was -0.51% lower at $43.24. During the past 52 weeks, the stock has ranged from a high of $48.00 to a low of $36.91. So far this year, shares have gained +5.57% and 1-year performance stands around +12.2%. Merck & Co., Inc. provides various health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. The company provides human health pharmaceutical products, such as therapeutic and preventive agents for the treatment of human disorders in the areas of cardiovascular.
Why Should Investors Buy MRK After the Recent Fall? Just Go Here and Find Out
About Universal Penny Stocks
universalpennystocks.com is an Independent Company, our focus is on small cap stocks that trade on OTCBB and OTC markets, and are mostly referred to as “penny stocks”. These are stocks that normally trade under $5 a share and could offer the greatest potential return on your short or long term investment. You must read our Disclaimer page for more information regarding conflicts of interest and the risks involved.
We try to spot stocks in all types of market conditions. In addition, we provide emerging small cap companies with profiling and investor relations services for compensation. If you believe your company is an emerging company, with a solid product, or a company that offers our members a profitable short or long term opportunity please feel free to send us an e-mail and we’ll review the company and reply to your inquiry promptly. Please provide as much information you believe we’ll need to review your request.
Copyright © 2005-2013 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-321-1250 (International)